PHASE III STUDY OF DOSE REGIMEN IN INITIAL NEUROLOGICAL WILSON'S DISEASE
PHASE III STUDY OF DOSE REGIMEN IN INITIAL NEUROLOGICAL WILSON'S DISEASE
批准号:
7603705
负责人:
GEORGE J BREWER
金额:
$17.71万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-03-01 至 2007-09-16
关键词:
AcuteAdverse effectsAnemiaBloodBrainBrain InjuriesChildClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseCopperDevelopmentDoseDouble-Blind MethodElevationEnzymesEthnic groupEvaluationFemaleFundingGrantHepatolenticular DegenerationHome environmentHospitalsIncidenceInstitutionLeukopeniaLiverMaintenance TherapyMichiganMinorNervous System PhysiologyNeurologicPatientsPenicillaminePharmaceutical PreparationsPhasePlacebosProtocols documentationRandomizedResearchResearch PersonnelResourcesSourceStandards of Weights and MeasuresSymptomsTestingTimeToxic effectTransaminasesTreatment EfficacyTreatment ProtocolsTriethylenetetramineUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesVisitWeekZincfollow-uphypocupremiamaletetrathiomolybdate
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
我们过去的研究已经导致FDA批准锌用于肝豆状核变性的维持治疗。锌现在可以取代毒性大得多的青霉胺和曲恩汀。当威尔逊病患者首次出现急性铜中毒疾病时,锌的作用太慢了。这些患者可能因脑损伤或肝脏损伤而患上急病。对于表现为脑(神经)发育的患者,我们正在开发一种安全、快速和有效的新药四硫钼酸(TM)。然而,大约12%的患者出现铜缺乏的症状(贫血、白细胞减少),在目前的剂量方案下,12%的患者出现转氨酶轻度升高。通过减少TM剂量,这两种轻微副作用都很容易逆转。我们开发了这种双盲方案来测试一种新的剂量方案,该方案在更长的时间内提供比标准方案更低的TM剂量,希望在保持治疗效果的同时消除这些副作用。
我们将包括所有患者(包括儿童),包括男性和女性,所有种族在这项研究中。他们将被随机分配标准TM方案或改进的TM剂量方案。所有患者也将接受锌治疗。患者将在密歇根大学医院的综合临床研究中心住大约6周,然后在家里再接受10周的药物治疗。每两周将在家中抽血进行持续评估。治疗16周后,患者将返回密歇根大学进行随访。接受传统TM剂量的患者在TM治疗8周后将继续接受锌维持治疗。他们将接受TM-安慰剂,直到第16周。接受新TM方案的患者将在TM治疗16周后过渡到锌维持治疗。
如果这项研究表明新的TM剂量方案对这类患者是一种更好的治疗方案,它将减少过度治疗的发生率和转氨酶升高,同时保护患者的神经功能。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Our past research has led to the development of an FDA approval of zinc for maintenance therapy of Wilson's disease. Zinc can now replace penicillamine and trientine, which have much more toxicity. Zinc is too slow acting for treating Wilson's disease patients when they first present with acute copper toxicity illness. These patients may be acutely ill from brain damage or liver damage. For the patients presenting with brain (neurologic) development, we are well along on developing a new drug, tetrathiomolybdate (TM), which is safe, fast-acting, and effective. However, approximately 12% of patients develop symptoms of copper deficiency (anemia, leukopenia), and 12% of patients develop mild elevations in transaminase enzymes under the current dose regimen. Both of these minor side effects are readily reversible by reducing the TM dose. We have developed this double-blind protocol to test a new dose regimen, which gives a lower dose of TM over a longer period of time than the standard regimen, in the hope of eliminating these side effects while preserving the efficacy of the treatment.
We will include all patients (including children), both males and females, all ethnic groups in this study. They will be randomly assigned either the standard TM regimen or the modified TM dose regimen. All patients will receive zinc as well. Patients will be in the General Clinical Research Center of University of Michigan Hospital for about 6 weeks, then receive the drugs at home for another 10 weeks. Blood will be drawn every two weeks at home for continuing evaluation. After 16 weeks of therapy, patients will return to UM for a follow-up visit. Patients receiving the traditional TM dose will be kept on zinc maintenance therapy after 8 weeks of TM. They will receive a TM-placebo with the zinc until week 16. Patients on the new TM regimen will be transitioned to zinc maintenance therapy after 16 weeks of TM treatment.
If this study shows the new TM dose regimen to be a superior treatment for this kind of patient, it will decrease the incidence of overtreatment and transaminase enzyme elevations, while preserving the neurologic function of patients.'
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE III TRIAL OF TETRATHIOMOLYBDATE (TM) IN PRIMARY BILIARY CIRRHOSIS
-
批准号:7603793
-
项目类别:
-
资助金额:$1.56万
-
财政年份:2007
-
负责人:GEORGE J BREWER
-
依托单位:
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN INITIAL HEPATIC WILSON'S DISEASE
-
批准号:7603717
-
项目类别:
-
资助金额:$2.1万
-
财政年份:2007
-
负责人:GEORGE J BREWER
-
依托单位:
PHASE III STUDY OF DOSE REGIMEN IN INITIAL NEUROLOGICAL WILSON'S DISEASE
-
批准号:7376504
-
项目类别:
-
资助金额:$46.09万
-
财政年份:2006
-
负责人:GEORGE J BREWER
-
依托单位:
THERAPY OF WILSON'S DISEASE WITH TETRATHIOMOLYBDATE - COMPARISON WITH TRIENTINE
-
批准号:7376491
-
项目类别:
-
资助金额:$0.46万
-
财政年份:2006
-
负责人:GEORGE J BREWER
-
依托单位:
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN INITIAL HEPATIC WILSON'S DISEASE
-
批准号:7376522
-
项目类别:
-
资助金额:$8.58万
-
财政年份:2006
-
负责人:GEORGE J BREWER
-
依托单位:
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN PRIMARY BILIAR*
-
批准号:7127948
-
项目类别:
-
资助金额:$29.65万
-
财政年份:2005
-
负责人:GEORGE J BREWER
-
依托单位:
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN PRIMARY BILIAR*
-
批准号:7474013
-
项目类别:
-
资助金额:$30.31万
-
财政年份:2005
-
负责人:GEORGE J BREWER
-
依托单位:
PHASE III STUDY OF DOSE REGIMEN IN INITIAL NEUROLOGICAL WILSON'S DISEASE
-
批准号:7199819
-
项目类别:
-
资助金额:$38.34万
-
财政年份:2005
-
负责人:GEORGE J BREWER
-
依托单位:
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN INITIAL HEPATIC WILSON'S DISEASE
-
批准号:7199838
-
项目类别:
-
资助金额:$12.97万
-
财政年份:2005
-
负责人:GEORGE J BREWER
-
依托单位:
THERAPY OF WILSON'S DISEASE WITH TETRATHIOMOLYBDATE - COMPARISON WITH TRIENTINE
-
批准号:7199797
-
项目类别:
-
资助金额:$4.01万
-
财政年份:2005
-
负责人:GEORGE J BREWER
-
依托单位:
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN PRIMARY BILIAR*
-
批准号:7460524
-
项目类别:
-
资助金额:$30.62万
-
财政年份:2005
-
负责人:GEORGE J BREWER
-
依托单位:
Phase III Trial of Tetrathiomolybdate in Initial Hepatic Wilson's Disease
-
批准号:7039810
-
项目类别:
-
资助金额:$16.93万
-
财政年份:2004
-
负责人:GEORGE J BREWER
-
依托单位:
Therapy of Wilson's Disease with Tetrathiomolybdate - Comparison with Trientine
-
批准号:7039739
-
项目类别:
-
资助金额:$5.18万
-
财政年份:2004
-
负责人:GEORGE J BREWER
-
依托单位:
Phase III Study of Dose Regimen in Initial Neurological Wilson's Disease
-
批准号:7039781
-
项目类别:
-
资助金额:$61.45万
-
财政年份:2004
-
负责人:GEORGE J BREWER
-
依托单位:
THERAPY OF WILSONS DISEASE W/ TETRATHIOMOLYBDATE COMPARISON W/ TRIENTINE
-
批准号:6303500
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1999
-
负责人:GEORGE J BREWER
-
依托单位:
CANINE GENE DISCOVERY AND EPILEPSY THERAPY
-
批准号:2794952
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1999
-
负责人:GEORGE J BREWER
-
依托单位:
TREATMENT OF WILSONS DISEASE WITH ZINC
-
批准号:6297073
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1998
-
负责人:GEORGE J BREWER
-
依托单位:
THERAPY OF WILSONS DISEASE W/ TETRATHIOMOLYBDATE COMPARISON W/ TRIENTINE
-
批准号:6297070
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1998
-
负责人:GEORGE J BREWER
-
依托单位:
INITIAL THERAPY OF WILSON'S DISEASE WITH AMMONIUM TETRATHIOMOLYBDATE
-
批准号:6297079
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1998
-
负责人:GEORGE J BREWER
-
依托单位:
INITIAL THERAPY OF WILSON'S DISEASE WITH AMMONIUM TETRATHIOMOLYBDATE
-
批准号:6113345
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1998
-
负责人:GEORGE J BREWER
-
依托单位:
海外基金